What Xenopat does is implant human tumors into the same organ they are originally from: lung tumors into the mouse’s lungs, ovarian tumors into its ovaries, thus avoiding the issue for the most part...
Read moreThe new drug, called tenofovir alafenamide does not generate long-term toxicity in the tissues of patients with HIV since it is not metabolized in the blood, but does so directly into lymphoid cells
Read moreIt presents the possibility of using plants to look for compounds capable of regulating the telomeres in animal cells that could be useful in the treatment of illnesses associated with ageing, includi...
Read moreThere is increasing evidence that proteins in the extracellular matrix (ECM) play a fundamental role in neural development and regeneration, synaptic plasticity, neuronal excitability and neural netwo...
Read moreAccording to the Spanish Association Against Cancer, around 20,000 cases are diagnosed each year in Spain, representing 18.4% of all tumors in men - 18,000 cases - and 3.2% in women - 2,000 cases -.
Read moreEl estudio ha permitido obtener un sistema antifúngico con las mejores características con el que mantener los niveles terapéuticos durante un período de tiempo más largo
Read moreScientists from IrsiCaixa AIDS Research Institute, jointly promoted by the Obra Social "la Caixa" and the Health Department of the Generalitat de Catalunya, have proved that a family of immune system ...
Read moreLa enfermedad inflamatoria intestinal es una dolencia crónica, progresiva y que genera una gran discapacidad. La importancia de avanzar en la investigación de nuevos tratamientos queda de relieve en...
Read moreEl estudio muestra una tasa de control de la enfermedad del 67% y apunta que los anticuerpos de Sym004 consiguen una penetración superior y, por tanto, mejores resultados que el cetuximab o el panitu...
Read moreThe therapeutic vaccine designed by IrsiCaixa researchers is the very first one developed according to the immune response of people who control HIV without antiretroviral treatment. Phase I trials wi...
Read moreUn estudio con participación del ICO Badalona que publica The New England Journal of Medicine muestra que el 19% de los pacientes con cáncer de pulmón responden a la inmunoterapia
Read moreEl presupuesto global para este proyecto es de un millón de euros y tendrá una duración de cuatro años, a contar a partir del 1 de febrero de 2015
Read more